Ubiquitin C‑terminal hydrolase‑L1: A new cancer marker and therapeutic target with dual effects (Review)
Oncology Letters · 08.02.2023 · 25 (3)
DOI: 10.3892/ol.2023.13709 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncology Letters, online erschienen am 08.02.2023. Verfasst von Xiaowei Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China. Die Arbeit wurde bisher 30-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
- Department of The Second Clinical Medical College of Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
- Department of Neurology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
Zitieren
APA
Wang, X., Zhang, N., Li, M., Hong, T., Meng, W., & Ouyang, T. (2023). Ubiquitin C‑terminal hydrolase‑L1: A new cancer marker and therapeutic target with dual effects (Review). Oncology Letters, 25(3). https://doi.org/10.3892/ol.2023.13709
Vancouver
Wang X, Zhang N, Li M, Hong T, Meng W, Ouyang T. Ubiquitin C‑terminal hydrolase‑L1: A new cancer marker and therapeutic target with dual effects (Review). Oncology Letters. 2023;25(3). doi:10.3892/ol.2023.13709
BibTeX
@article{Wang2023,
author = {Wang, Xiaowei and Zhang, Na and Li, Meihua and Hong, Tao and Meng, Wei and Ouyang, Taohui},
title = {Ubiquitin C‑terminal hydrolase‑L1: A new cancer marker and therapeutic target with dual effects (Review)},
journal = {Oncology Letters},
year = {2023},
volume = {25},
number = {3},
doi = {10.3892/ol.2023.13709}
}
EUVIMED